Allergy company DBV raises $150M

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) raised $150 million through the sale of 2.8 million ADSs at $21.26 in a follow-on and 2.1 million shares at €34.71 in a concurrent private placement. The offer was underwritten by Morgan Stanley, Goldman Sachs, Barclays, Deutsche Bank and Bryan, Garnier & Co. The ADS price was a 3% discount to DBV's NASDAQ closing price of $22.01 on Tuesday, when the company proposed the offering after market close.

In February, DBV announced plans to submit a BLA in 2H18 for Viaskin Peanut (DBV-712) to treat peanut allergy in patients ages 4-11 (see BioCentury Extra, Feb. 14)...